Ethyl eicosapentaenoic acid

Drug Profile

Ethyl eicosapentaenoic acid

Alternative Names: eicosapentaenoic acid ethyl ester; EPA-E; Epadel; Epadel-T; ethyl icosapentaenoate; ethyl icosapentate; MND-21

Latest Information Update: 24 Aug 2015

Price : $50

At a glance

  • Originator Mochida Pharmaceutical
  • Class Antidepressants; Antihyperlipidaemics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Caspase inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Hyperlipidaemia
  • Clinical Phase Unknown Chronic heart failure
  • Discontinued Alzheimer's disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Apr 2014 Clinical trial in Chronic heart failure in Japan (PO)
  • 31 Oct 2012 Mochida Pharmaceutical Company completes a phase II trial in Non-alcoholic steatohepatitis in USA and Puerto Rico (NCT01154985)
  • 30 Jun 2010 Phase-II clinical trials in Non-alcoholic steatohepatitis in Puerto Rico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top